System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Raúl J Andrade is an expert in Hepatology at Hospital Clínico Universitario Virgen de la Victoria (Spain). As of October 2026, ScienceLeadR ranks Raúl J Andrade in the top 1% of experts worldwide for Hepatitis. Raúl J Andrade has authored 490 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 1,773 (community average: 125). How the SLR is computed.

LeadR Profile

Raúl J Andrade Hospital Clínico Universitario Virgen de la Victoria Spain
1 773 ScienceLeadR Reputation 1773

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Pharmacy - Gastroenterology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026
Source: PubMed

Hospital Clínico Universitario Virgen de la Victoria

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 490

Citations

Citations: 25 120 1st author: 57 Last author: 111 Unique author: 6

Main journals

J Hepatol 108
Gastroenterol Hepatol 26
Liver Int 21
Hepatology 19
Rev Esp Enferm Dig 18

Best Journals

J Hepatol 24
N Engl J Med 3
Nat Rev Gastroenterol Hepatol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinical Significance of Acute Kidney Injury in Idiosyncratic Drug-Induced Liver Injury: A Multicentric Propensity Scores Matched Study.
PMID 42609216 — registries, comorbidity, mortality, incidence, pharmaceutical preparations, lymphopenia, propensity score, kidney, drug therapy, liver, pharmacology, risk factors, acute kidney injury		Clin Pharmacol Ther20260
Tolebrutinib liver safety: A detailed overview.
PMID 42546561 — multiple sclerosis, safety, liver		Mult Scler Relat Disord20260
Artificial intelligence predicts recurrent autoimmune hepatitis after liver transplantation in a multicenter cohort study.
PMID 42520166 — liver diseases, hepatitis, autoimmune, liver transplantation, intelligence, cohort studies, liver, machine learning, transplants, artificial intelligence, transplantation, hepatitis		Hepatol Commun20260
Beyond Hy's Law: Importance of Markedly Elevated Aminotransferases without Hyperbilirubinemia.
PMID 42502235 — registries, hyperbilirubinemia, jaundice, drug therapy, transaminases, liver, pharmacology, bilirubin		Clin Pharmacol Ther20261
The gut-liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system.
PMID 42453403 — pharmaceutical preparations, homeostasis, liver, immune system, gastrointestinal microbiome, microbiota		Acta Pharm Sin B20261

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 4
Phase 2 3
N/A 2

By status:

Completed 5
Unknown 2
Recruiting 1
Terminated 1

By type:

Interventional 7
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 11

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Global Randomized Open label Multicenter Phase 3 Trial Evaluating BJT 778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE 2)
2024-517167-23-00 — hepatitis d, hepatitis d, chronic, hepatitis, chronic, therapeutics, infections, hepatitis		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS